

marrow, it is suggested that the use of the drug in large doses intravenously may carry a greater risk of bone marrow toxicity than its use by mouth.

ALAN C. GIBSON.

*St. Ann's Hospital,
Haven Road,
Canford Cliffs,
Poole, Dorset, BH13 7LN.*

BRITISH ACADEMY OF
PSYCHOPHARMACOLOGY

DEAR SIR,

Further to the letter from the Steering Committee (*Journal*, May 1974, 124, 508), I write to say that the inaugural meeting was held on 22 April last and the Academy formally constituted.

As a result of the Steering Committee's letter, we received 129 letters supporting the formation of the Academy, and one letter against its formation. The inaugural meeting was attended by 45 interested

persons. Letters of congratulation and support were received from the Presidents of the following Colleges of Neuropsychopharmacology: International (C.I.N.P.), American (A.C.N.P.), German (A.G.N.P.) and Turkish (T.C.N.P.).

Professor Max Hamilton was elected first President of the Academy, and Dr. Alec Coppen, President Elect. Other officers and a council of ten members were also elected. It was decided that one of the main objects of the Academy would be to provide a means of integrating the many disciplines involved in psychopharmacological research, although there would be some emphasis on clinical psychopharmacology. To this end, applications for membership will be considered from interested persons, and any of your readers who make like further details are invited to write to the undersigned.

DAVID WHEATLEY,
Honorary Secretary.

*325 Staines Road,
Twickenham, TW2 5AX.*